research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
This article incorporates text by Laura J. Cobb, Changhan Lee, Jialin Xiao, Kelvin Yen, Richard G. Wong, Hiromi K. Nakamura, Hemal H. Mehta, Qinglei Gao, Carmel Ashur, Derek M. Huffman, Junxiang Wan, Radhika Muzumdar, Nir Barzilai, and Pinchas Cohen2 available under the CC BY 4.0 license.
The two substrates of this enzyme are L-threonine and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (S)-2-amino-3-ketobutyric acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-threonine:NAD+ oxidoreductase. Other names in common use include L-threonine dehydrogenase, and threonine 3-dehydrogenase.
=== Naturally occurring === ACE inhibitor peptides can be derived from natural sources such as algae, fruit, seeds, dairy and animal products. A comprehensive resource on anti-hypertensive peptides is available in the form of a database. It contains around 1700 unique antihypertensive peptides. Arfalasin (HOE 409) is an angiotensin antagonist.
1 by the Secretary of State for Home Affairs 1 by the Minister for Transport 6 by the London County Council: 1 by the Corporation of the City of London 1 by the Council of the City of Westminster 6 by the councils of the remaining metropolitan boroughs 2 by the Middlesex County Council 2 by the Essex County Council 1 by the Kent County Council 1 by the Surrey County Council 1 (jointly) by the Buckinghamshire and Hertfordshire County Councils 1 by the Council of the County Borough of Croydon 1 by the Council of the County Borough of East Ham 1 by the Council of the County Borough of West Ham 1 the Secretary of State for Home Affairs to represent the Metropolitan Police 1 the Secretary of State for Home Affairs to represent county and borough police forces in the London Traffic Area 1 by the Corporation of the City of London to represent the City Police 2 by the London Passenger Transport Board 2 by the amalgamated railway companies 5 by the Minister of Labour "after consultation with such bodies representative of those interests as he may think fit to represent the interests of labour engaged in the transport industry within the London Traffic Area" 1 by the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of persons (other than the Board and the amalgamated railway companies) providing or using mechanically-propelled road vehicles within the London Traffic Area" 1 the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of persons (other than the Board and the amalgamated railway companies) providing or using horse-drawn road vehicles within the London Traffic Area" 1 the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of the taxi-cab industry within the London Traffic Area"
Sources: en.wikipedia.org
=== Ground === Ground stainless steel belts are normally produced with surface roughness ranging from 0.4 μm down to 0.1 μm, with well-rounded edges, and developed for level and straight contour. Such belts are supplied in open lengths, with the ends prepared for welding on site, or in endless condition with a welded joint.
No. (number) column A running positive integer for reference, equal to the position in the tables. This number may change in the future, especially for nuclides with short lives, as better half-life estimates become available.
While negotiating with Alpachi for the hostages' release, Umeko realizes the truth and clears his name, while her teammates rescue Alpachi's son and delete Goldom. Attika Alpachi is voiced by Bin Shimada. Shinnooian Hakutaku (シンノー星人ハクタク, Shinnō Seijin Hakutaku): A wise woman from Planet Shinoo, with knowledge of all space herbs, who occasionally assumes the form of a human teenage girl and possesses a third eye shaped like a red jewel. After the Dekarangers take her into their protective custody, she provides guidance to Sen-chan, becomes attracted to him, and raises money for their wedding. Hakutaku is voiced by Reiko Suzuki (鈴木 れい子, Suzuki Reiko) while her human form is portrayed by Narumi Konno (近野 成美, Kon'no Narumi). Bandarean Jeeva (バンダレ星人ジーバ, Bandare Seijin Jība): A physically imposing Oni-themed alien, and champion boxer in Durden's illegal fight club, from Planet Bandare. After consuming Durden's steroid, Megagesterine, and gaining wing-like horns on his arms and neck, Jeeva fights Hoji, who defeats him. Following this, Jeeva reformed and found work as the assistant director of a television station. Jeeva is voiced by Toshitsugu Takashina (高階 俊嗣, Takashina Toshitsugu). Slorpean Faraway (スロープ星人ファラウェイ, Surōpu Seijin Farawei): A small-time criminal from Planet Slorpe who resembles a ganguro girl and possesses proficient hacking skills.
Ethical vegetarians believe that killing an animal, like killing a human, especially one who has equal or lesser cognitive abilities than the animals in question, can only be justified in extreme circumstances and that consuming a living creature for its enjoyable taste, convenience, or nutrition value is not a sufficient cause. Another common view is that humans are morally conscious of their behavior in a way other animals are not, and therefore subject to higher standards. Jeff McMahan proposes that denying the right to life and humane treatment to animals with equal or greater cognitive abilities than mentally disabled humans is an arbitrary and discriminatory practice based on habit instead of logic. Opponents of ethical vegetarianism argue that animals are not moral equals to humans and so consider the comparison of eating livestock with killing people to be fallacious. This view does not excuse cruelty, but maintains that animals do not possess the rights a human has.
== Spiking studies == In many cases, the concentration of viruses in a given sample is extremely low. In other extraction processes, low levels of impurity may be negligible, but because viruses are infective impurities, even one viral particle may be enough to ruin an entire process chain. It is for this reason that special measures must be taken to determine the appropriate removal or inactivation method for whatever type of virus is being extracted from whatever type of solution. Spiking studies were created specifically for this purpose. A spiking study is a study done in order to determine the possible methods of viral removal or inactivation. The results of these studies are numerical and, based on these numbers, researchers can determine whether or not the process on which the study was conducted will be suitable for the viruses they are trying to extract and the solution from which they are trying to extract them.
Sources: en.wikipedia.org
=== Alumoxanes === Following from his work on the chalcogenides, Barron was the first person to crystallographically characterize an alkylalumoxane in 1993. These structures were spectroscopically consistent with methylalumoxane and he showed that despite being octet molecules they had significant Lewis acidity, he termed this as "Latent Lewis acidity", and showed that this mechanism applied to a number of MAO style polymerization systems. Barron's 3-dimensional model has been evolved by others but is essentially the same as now widely accepted.
226Ra occurs in the decay chain of uranium-238 (238U), which is the most common naturally occurring isotope of uranium. It undergoes alpha decay to radon-222, which is also radioactive; the decay chain ultimately terminates at lead-206. Because of its occurrence in the 238U decay chain, 226Ra exists naturally at low concentrations not only in uranium-containing minerals, but universally diffused in the environment (as also is uranium), as in soil and groundwater.
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. It is a standard measurement in pharmacokinetics.
The Economist reports that China has become a "scientific superpower", citing numerous examples of its rapid development across a wide range of fields. 20 June – Following a surge in population of the Iberian lynx – from 62 mature individuals in 2001 to 648 in 2022 – the International Union for Conservation of Nature removes the animal from its "endangered" list, classing the animal as "vulnerable" instead. 24 June – The discovery of three Super-Earth candidates around HD 48948, a K-type dwarf star located 55 light-years away, is reported. One planet lies within the habitable zone. 25 June – China's Chang'e 6 lunar exploration mission successfully returns to Earth after taking rock and soil samples from the far side of the Moon. The orbiter proceeded on a mission to carry out observations at Sun-Earth Lagrange point L2 after dropping the sample off to Earth. Promising results of health and medical research are reported: a blood AI test of plasma proteins that predicts Parkinson's disease up to 7 years before symptom onset (18 June), walking programs as a cost-effective method against lower back pain recurrence (19 June). Hazard research is published: a study finds toxic metals including lead and arsenic in tampons (22 June), and a study indicates ocean water intrusion causing Antarctic ice-sheet grounding zones melting is a further tipping point in the climate system (25 June).
Silica gel particles have a high surface area for interactions to take place, either with solutes or bonding with ligands. Silica gel does not react with many types of solvents and analytes. Silica gel can be modified with various functional groups. Silica gel is cheap. Silica gel particles are easy to engineer into specific diameters, shapes, pore sizes, etc. The silica particle can have different shapes. The particle can be fully solid ("monolithic" or "fused"), full of holes ("porous"), or have a solid core and a porous shell ("superficially porous"). The particle can have different diameters. The pores can have different diameters. The United States Pharmacopoeia (USP) has classified HPLC columns by L# types. The most popular column in this classification is an octadecyl carbon chain (C18)-bonded silica (USP classification L1). This is followed by C8-bonded silica (L7), pure silica (L3), cyano-bonded silica (CN) (L10) and phenyl-bonded silica (L11). Note that C18, C8 and phenyl are dedicated reversed-phase stationary phases, while CN columns can be used in a reversed-phase mode depending on analyte and mobile phase conditions. Not all C18 columns have identical retention properties. Surface functionalization of silica can be performed in a monomeric or a polymeric reaction with different short-chain organosilanes used in a second step to cover remaining silanol groups (end-capping). While the overall retention mechanism remains the same, subtle differences in the surface chemistries of different stationary phases will lead to changes in selectivity.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.